JOP20230090A1 - نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم - Google Patents

نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم

Info

Publication number
JOP20230090A1
JOP20230090A1 JOJO/P/2023/0090A JOP20230090A JOP20230090A1 JO P20230090 A1 JOP20230090 A1 JO P20230090A1 JO P20230090 A JOP20230090 A JO P20230090A JO P20230090 A1 JOP20230090 A1 JO P20230090A1
Authority
JO
Jordan
Prior art keywords
hair loss
deuterium
systems
treating hair
loss disorders
Prior art date
Application number
JOJO/P/2023/0090A
Other languages
Arabic (ar)
English (en)
Inventor
James V Cassella
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of JOP20230090A1 publication Critical patent/JOP20230090A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOJO/P/2023/0090A 2020-10-28 2023-04-27 نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم JOP20230090A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US202163155637P 2021-03-02 2021-03-02
PCT/US2021/057123 WO2022094133A1 (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
JOP20230090A1 true JOP20230090A1 (ar) 2023-04-27

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0090A JOP20230090A1 (ar) 2020-10-28 2023-04-27 نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم

Country Status (14)

Country Link
US (1) US20230390292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023553253A (cg-RX-API-DMAC7.html)
KR (1) KR20230093504A (cg-RX-API-DMAC7.html)
AU (1) AU2021372512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001201A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006808A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000085A (cg-RX-API-DMAC7.html)
IL (1) IL302401A (cg-RX-API-DMAC7.html)
JO (1) JOP20230090A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005027A (cg-RX-API-DMAC7.html)
PE (1) PE20231945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022094133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215520A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
MX2023005027A (es) 2023-07-31
AU2021372512A1 (en) 2023-06-22
JP2023553253A (ja) 2023-12-21
US20230390292A1 (en) 2023-12-07
PE20231945A1 (es) 2023-12-05
EP4236956A1 (en) 2023-09-06
CO2023006808A2 (es) 2023-09-08
CA3196551A1 (en) 2022-05-05
CL2023001201A1 (es) 2023-11-17
IL302401A (en) 2023-06-01
DOP2023000085A (es) 2023-07-31
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
KR20230093504A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2024000820A (es) Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos.
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
JOP20250258A1 (ar) مثبطات 2-آزا باي سيكلو هبتان kras
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
ZA202403388B (en) Small molecules for treatement of cancer
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
JOP20230170A1 (ar) مثبطات cdk2 وطرق لاستخدامها
MX2025003908A (es) Compuesto inhibidor de parg
MY209389A (en) Use of bi853520 in cancer treatment
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2022000545A (es) Inhibidores de enzimas.
CL2023001201A1 (es) Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
MX2025006420A (es) Inhibidores de adar1 y métodos de uso de estos
JOP20250005A1 (ar) مثبطات التيروسين كيناز 2 واستخداماتها
MX2024013641A (es) Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak
GEAP202516658A (en) Ripk1 inhibitors and methods of use
MX2025001316A (es) Tratamiento de la urticaria con inhibidores de la cinasa de janus (jak)
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
EP4577535A4 (en) JAK1/JAK2/TYK2 INHIBITORS FOR THE TOPICAL TREATMENT OF DERMATOLOGICAL DISEASES